AZ, Merck's Lynparza scores data worth a shot at $1B boost by Tracy Staton Wednesday, June 27, 2018 AstraZeneca and Merck are eyeing a $1 billion boost for Lynparza, thanks to a trial win for women who have just been diagnosed with ovarian cancer.
AstraZeneca revs up for quick FDA review on new Lynparza use by Tracy Staton Tuesday, March 28, 2017 Hot on the heels of Tesaro's FDA nod for Zejula in ovarian cancer, AstraZeneca has nabbed priority review for its med Lynparza in the same treatment setting.
AZ's Lynparza fends off ovarian cancer by Tracy Staton Tuesday, March 14, 2017 AstraZeneca’s Lynparza honed its edge in ovarian cancer on Tuesday, just in time to help preserve its lead in the marketplace.
